Panelists discuss how risk stratification tools and patient-specific factors guide treatment selection and timing of interventions for patients with newly diagnosed intermediate 2–risk myelofibrosis, with a focus on optimizing clinical outcomes.
The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.
Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.
Bevacizumab’s survival benefits in CRC patients persist for about 2 years after starting treatment.
First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.
Zhang et al. investigate immune cell dynamics in TNBC patients treated with paclitaxel, nab-paclitaxel, and combinations with atezolizumab. They identify distinct underlying cellular mechanisms, revealing that…
Although gallbladder and bile duct cancers are different diseases, they’re often discussed together. They each have a connection to bile, a fluid that helps with…
Get the inside scoop from Drs Lou, Patel, and Beg on the top takeaways to come out of the 2025 Gastrointestinal Cancers Symposium.
Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related cardiac events than those treated with other EGFR tyrosine kinase inhibitors.“Despite…
